UK Life Sciences Industrial Strategy Is Starting To Show Its Value In The Medtech Arena

UK strategies that have sought to maximize the partnership potential of medtech innovators and the country's National Health Service have often not lasted long enough to prove their worth. But Neil Mesher, Philips CEO of UK and Ireland, says the Life Sciences Industrial Strategy might just be different.

Collaboration across the NHS has been a focus for health-care economists, business leaders and NHS directors for 15 or more years. Many studies have been undertaken and publications released that aim to address the issues, and they have all tried to bring academia, health-care systems and industry together. But something has never been right, says Neil Mesher, Royal Philips NV CEO for the UK and Ireland.

Addressing delegates at a Nov. 6 conference marking the Association of British HealthTech Industries' (ABHI) 30th anniversary, Mesher said: "We now have an opportunity with the Life Science Industrial Strategy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe